Abstract
In the field of urogynecology, synthetic polypropylene (PP) meshes have seen an increase in use over the last decade. These devices are implanted in over 200,000 women annually and are designed to restore pelvic organ support for women suffering from pelvic organ prolapse (1). Because they are essentially modified abdominal hernia meshes, their use in the field urogynecology has undergone little oversight. With more patients experiencing morbidity, the FDA has released two Public Health Notifications in 2009 and 2011 informing the public about the potential complications associated with urogynecological mesh implantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
